advertisement

---

Trials 11

Showing records 1 to 11 | Display all abstracts in Trials

98560 Nicotinamide riboside as a neuroprotective therapy for glaucoma: study protocol for a randomized, double-blind, placebo-control trial
Leung CKS
Trials 2022; 23: 45

---

98455 Guided meditation for vision acuity training on adolescent myopia: study protocol for an open-label, prospective, multicenter, randomized controlled trial
Li Y; Zhu L
Trials 2022; 23: 16

---

98560 Nicotinamide riboside as a neuroprotective therapy for glaucoma: study protocol for a randomized, double-blind, placebo-control trial
Ren ST
Trials 2022; 23: 45

---

98455 Guided meditation for vision acuity training on adolescent myopia: study protocol for an open-label, prospective, multicenter, randomized controlled trial
Wang R
Trials 2022; 23: 16

---

98560 Nicotinamide riboside as a neuroprotective therapy for glaucoma: study protocol for a randomized, double-blind, placebo-control trial
Chan PPM; Wan KHN; Wan KHN
Trials 2022; 23: 45

---

98455 Guided meditation for vision acuity training on adolescent myopia: study protocol for an open-label, prospective, multicenter, randomized controlled trial
Yang X
Trials 2022; 23: 16

---

98560 Nicotinamide riboside as a neuroprotective therapy for glaucoma: study protocol for a randomized, double-blind, placebo-control trial
Kam AKW
Trials 2022; 23: 45

---

98455 Guided meditation for vision acuity training on adolescent myopia: study protocol for an open-label, prospective, multicenter, randomized controlled trial
Jiang X
Trials 2022; 23: 16

---

98560 Nicotinamide riboside as a neuroprotective therapy for glaucoma: study protocol for a randomized, double-blind, placebo-control trial
Lai GWK
Trials 2022; 23: 45

---

98455 Guided meditation for vision acuity training on adolescent myopia: study protocol for an open-label, prospective, multicenter, randomized controlled trial
Lu T
Trials 2022; 23: 16

---

98560 Nicotinamide riboside as a neuroprotective therapy for glaucoma: study protocol for a randomized, double-blind, placebo-control trial
Chiu VSM; Ko MWL; Ko MWL; Yiu CKF; Yu MCY
Trials 2022; 23: 45

---